The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...

Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $20.76 which represents a decrease of $-0.77 or -3.58% from the prior close of $21.53. The stock opened at $21.23 and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.53 which represents a slight increase of $1.82 or 9.23% from the prior close of $19.71. The stock opened at $20.05 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

S&P Dow Jones Indices said that Guidewire Software Inc. (GWRE) will replace Arrowhead Pharmaceuticals Inc. (ARWR) in the S&P MidCap ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the ...

On the other hand, Arrowhead Pharmaceuticals has entered into a significant strategic partnership with Sarepta Therapeutics, involving a $500 million upfront payment and a $325 million equity ...